Ubs Asset Management Americas Inc Arrowhead Pharmaceuticals, Inc. Transaction History

Ubs Asset Management Americas Inc

$477 Billion
Q2 2025

A detailed history of Ubs Asset Management Americas Inc transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 2,684,317 shares of ARWR stock, worth $114 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,684,317

Previous 4,785,062 43.9%

Holding current value

$114 Million

Previous $61 Million 30.43%

% of portfolio

0.01%

Previous 0.02%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$9.99 - $16.97 $21 Million - $35.6 Million	-2,100,745 Reduced 43.9%	2,684,317 $42.4 Million
Q1 2025 May 19, 2025	BUY	$12.74 - $21.53 $35.4 Million - $59.7 Million	2,774,933 Added 138.05%	4,785,062 $61 Million
Q4 2024 Feb 14, 2025	SELL	$17.7 - $26.34 $2.55 Million - $3.8 Million	-144,121 Reduced 6.69%	2,010,129 $37.8 Million
Q3 2024 Nov 14, 2024	SELL	$19.36 - $29.54 $2.63 Million - $4.01 Million	-135,904 Reduced 5.93%	2,154,250 $41.7 Million
Q2 2024 Aug 13, 2024	BUY	$21.87 - $28.24 $29.7 Million - $38.3 Million	1,356,254 Added 145.22%	2,290,154 $59.5 Million
Q1 2024 May 15, 2024	SELL	$27.21 - $39.48 $473,290 - $686,715	-17,394 Reduced 1.83%	933,900 $26.7 Million
Q4 2023 Feb 14, 2024	BUY	$21.2 - $31.03 $4.46 Million - $6.53 Million	210,412 Added 28.4%	951,294 $29.1 Million
Q3 2023 Nov 13, 2023	BUY	$26.2 - $36.08 $5.34 Million - $7.36 Million	203,917 Added 37.98%	740,882 $19.9 Million
Q1 2023 May 15, 2023	BUY	$23.68 - $38.51 $924,561 - $1.5 Million	39,044 Added 7.84%	536,965 $13.6 Million
Q4 2022 Feb 14, 2023	BUY	$28.0 - $40.56 $11.5 Million - $16.7 Million	411,561 Added 476.56%	497,921 $20.2 Million
Q3 2022 Nov 14, 2022	SELL	$29.63 - $48.31 $692,304 - $1.13 Million	-23,365 Reduced 21.29%	86,360 $2.85 Million
Q2 2022 Aug 12, 2022	SELL	$27.79 - $50.61 $115,634 - $210,588	-4,161 Reduced 3.65%	109,725 $3.86 Million
Q1 2022 May 16, 2022	BUY	$39.62 - $69.97 $664,704 - $1.17 Million	16,777 Added 17.28%	113,886 $5.24 Million
Q4 2021 Feb 14, 2022	SELL	$58.09 - $82.51 $80,338 - $114,111	-1,383 Reduced 1.4%	97,109 $6.44 Million
Q3 2021 Nov 15, 2021	BUY	$58.38 - $84.96 $632,313 - $920,201	10,831 Added 12.36%	98,492 $6.15 Million
Q2 2021 Aug 16, 2021	SELL	$62.15 - $90.32 $236,170 - $343,216	-3,800 Reduced 4.15%	87,661 $7.26 Million
Q1 2021 May 14, 2021	SELL	$61.35 - $90.47 $1.6 Million - $2.36 Million	-26,135 Reduced 22.22%	91,461 $6.06 Million
Q4 2020 Mar 01, 2021	BUY	$43.82 - $85.37 $502,922 - $979,791	11,477 Added 10.82%	117,596 $9.02 Million
Q3 2020 Nov 13, 2020	BUY	$33.21 - $51.27 $31,383 - $48,450	945 Added 0.9%	106,119 $4.57 Million
Q2 2020 Aug 14, 2020	BUY	$26.12 - $43.27 $425,155 - $704,305	16,277 Added 18.31%	105,174 $4.54 Million
Q1 2020 May 15, 2020	SELL	$20.56 - $63.12 $24,610 - $75,554	-1,197 Reduced 1.33%	88,897 $2.56 Million
Q4 2019 Feb 14, 2020	SELL	$28.14 - $73.01 $29,181 - $75,711	-1,037 Reduced 1.14%	90,094 $5.71 Million
Q3 2019 Nov 14, 2019	BUY	$26.26 - $34.86 $362,755 - $481,556	13,814 Added 17.87%	91,131 $2.57 Million
Q2 2019 Aug 15, 2019	BUY	$17.43 - $28.82 $629,955 - $1.04 Million	36,142 Added 87.78%	77,317 $0
Q1 2019 May 14, 2019	SELL	$12.05 - $20.18 $169,772 - $284,316	-14,089 Reduced 25.49%	41,175 $0
Q4 2018 Feb 13, 2019	SELL	$10.74 - $19.7 $128,901 - $236,439	-12,002 Reduced 17.84%	55,264 $686,000
Q3 2018 Nov 14, 2018	BUY	$14.0 - $20.3 $254,576 - $369,135	18,184 Added 37.05%	67,266 $0
Q2 2018 Aug 14, 2018	BUY	$6.37 - $14.02 $312,652 - $688,129	49,082 New	49,082 $0

Others Institutions Holding ARWR

# of Institutions

328

Shares Held

99.7M

Call Options Held

444K

Put Options Held

568K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $4.49B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Arrowhead Pharmaceuticals, Inc. Transaction History